{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:46:04Z","timestamp":1782607564204,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.yexcr.2026.115098","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:13:42Z","timestamp":1781021622000},"page":"115098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vactosertib reverses ABCG2-mediated multidrug resistance through dual inhibition of drug efflux and transporter expression"],"prefix":"10.1016","volume":"461","author":[{"given":"Zheshen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Duo","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6884-8890","authenticated-orcid":false,"given":"Yi-Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4005-9549","authenticated-orcid":false,"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haigan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2026.115098_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.yexcr.2026.115098_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.yexcr.2026.115098_bib3","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2026.115098_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.yexcr.2026.115098_bib5","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/humu.24418","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"43","author":"Dean","year":"2022","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.yexcr.2026.115098_bib6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature22345","article-title":"Structure of the human multidrug transporter ABCG2","volume":"546","author":"Taylor","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2026.115098_bib7","first-page":"1","article-title":"Human ABCG2: structure, function, and its role in multidrug resistance","volume":"3","author":"Mo","year":"2012","journal-title":"Int J Biochem Mol Biol"},{"key":"10.1016\/j.yexcr.2026.115098_bib8","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s11095-008-9537-z","article-title":"BCRP\/ABCG2 in the placenta: expression, function and regulation","volume":"25","author":"Mao","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.yexcr.2026.115098_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071376","article-title":"Transporter regulation in critical protective barriers: focus on brain and placenta","volume":"14","author":"Taggi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"Pt 11","key":"10.1016\/j.yexcr.2026.115098_bib10","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1242\/jcs.113.11.2011","article-title":"The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)","volume":"113","author":"Litman","year":"2000","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.yexcr.2026.115098_bib11","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2026.115098_bib12","first-page":"5538","article-title":"Wild-type breast cancer resistance protein (BCRP\/ABCG2) is a methotrexate polyglutamate transporter","volume":"63","author":"Volk","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2026.115098_bib13","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1158\/1078-0432.CCR-06-2414","article-title":"A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients","volume":"13","author":"Kuppens","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2026.115098_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.dmpk.2017.02.003","article-title":"Metabolism of KO143, an ABCG2 inhibitor","volume":"32","author":"Liu","year":"2017","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.yexcr.2026.115098_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112133","article-title":"Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP)","volume":"191","author":"Antoni","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.yexcr.2026.115098_bib16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/clpt.2011.217","article-title":"Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data","volume":"91","author":"Bauer","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yexcr.2026.115098_bib17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/jcp.55.5.332","article-title":"Multidrug resistance related molecules in human and murine lung","volume":"55","author":"Scheffer","year":"2002","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.yexcr.2026.115098_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fonc.2020.00228","article-title":"Reversal effect of ALK inhibitor NVP-TAE684 on ABCG2-Overexpressing cancer cells","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.yexcr.2026.115098_bib19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1124\/dmd.119.086975","article-title":"Interactions of alectinib with human ATP-Binding cassette drug efflux transporters and cytochrome P450 biotransformation enzymes: effect on pharmacokinetic multidrug resistance","volume":"47","author":"Hofman","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.yexcr.2026.115098_bib20","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/j.1476-5381.2012.01849.x","article-title":"Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein","volume":"166","author":"Zhou","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yexcr.2026.115098_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217309","article-title":"Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: in vitro and in vivo studies","volume":"607","author":"Dong","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.yexcr.2026.115098_bib22","article-title":"Reversal of ABCG2-mediated drug resistance by tinodasertib (ETC-206)","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yexcr.2026.115098_bib23","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1158\/1535-7163.MCT-13-0903","article-title":"EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis","volume":"13","author":"Son","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.yexcr.2026.115098_bib24","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1038\/s41467-024-51442-2","article-title":"The TGF\u03b2 type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed\/refractory multiple myeloma: a phase 1b trial","volume":"15","author":"Malek","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yexcr.2026.115098_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.607275","article-title":"Establishment and characterization of a topotecan resistant non-small cell lung cancer NCI-H460\/TPT10 cell line","volume":"8","author":"Lei","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.yexcr.2026.115098_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0304-3835(99)00182-2","article-title":"Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter","volume":"146","author":"de Bruin","year":"1999","journal-title":"MXR. Cancer Letters"},{"key":"10.1016\/j.yexcr.2026.115098_bib27","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6601370","article-title":"Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity","volume":"89","author":"Robey","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yexcr.2026.115098_bib28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2018.10.007","article-title":"Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells","volume":"440\u2013441","author":"Ji","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.yexcr.2026.115098_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2025.114851","article-title":"Overcoming multidrug resistance in cancer cells targeting ABC transporter ABCB1 with tyrosine kinase inhibitor: olverembatinib","volume":"455","author":"Zhang","year":"2026","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.yexcr.2026.115098_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101065","article-title":"ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C","volume":"73","author":"Lei","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.yexcr.2026.115098_bib31","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.3390\/ijms20174095","article-title":"Chk1 inhibitor MK-8776 restores the sensitivity of chemotherapeutics in P-glycoprotein overexpressing cancer cells","volume":"20","author":"Cui","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2026.115098_bib32","article-title":"Tivantinib, A c-Met inhibitor in clinical trials, is susceptible to ABCG2-Mediated drug resistance","volume":"12","author":"Wu","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.yexcr.2026.115098_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cancergen.2025.12.001","article-title":"Genetic modulation of ABCB1: sunvozertinib reverses ABCB1-mediated multidrug resistance in cancer cells","volume":"300\u2013301","author":"Cao","year":"2026","journal-title":"Cancer Genet."},{"key":"10.1016\/j.yexcr.2026.115098_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ijc.11528","article-title":"Reversal of breast cancer resistance protein (BCRP\/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic","volume":"108","author":"Shiozawa","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexcr.2026.115098_bib41","doi-asserted-by":"crossref","first-page":"93785","DOI":"10.18632\/oncotarget.21078","article-title":"Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: in vitro and in vivo studies","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.yexcr.2026.115098_bib42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/cancers12020429","article-title":"ABCG2 overexpression contributes to pevonedistat resistance","volume":"12","author":"Kathawala","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.yexcr.2026.115098_bib43","doi-asserted-by":"crossref","first-page":"47980","DOI":"10.1074\/jbc.M207857200","article-title":"Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation","volume":"277","author":"Ozvegy","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yexcr.2026.115098_bib44","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2217\/fon.13.253","article-title":"Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP)","volume":"10","author":"Yang","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.yexcr.2026.115098_bib45","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1042\/bj20030150","article-title":"A functional study on polymorphism of the ATP-Binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport","volume":"373","author":"Mitomo","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.yexcr.2026.115098_bib46","first-page":"6635","article-title":"Acquired mutations in the MXR\/BCRP\/ABCP gene alter substrate specificity in MXR\/BCRP\/ABCP-overexpressing cells","volume":"61","author":"Honjo","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2026.115098_bib47","first-page":"417","article-title":"Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C","volume":"1","author":"Allen","year":"2002","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.yexcr.2026.115098_bib48","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/acschembio.4c00353","article-title":"Modulation of ABCG2 transporter activity by Ko143 derivatives","volume":"19","author":"Yu","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.yexcr.2026.115098_bib49","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cmdc.201100543","article-title":"Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K\/Akt signaling pathway","volume":"7","author":"Pick","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.yexcr.2026.115098_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005676","article-title":"A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy","volume":"4","author":"Peng","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2026.115098_bib51","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.apsb.2021.12.018","article-title":"MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: in vitro and in vivo study","volume":"12","author":"Wu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.yexcr.2026.115098_bib52","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/mol.111.075556","article-title":"Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance","volume":"81","author":"Ding","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.yexcr.2026.115098_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101298","article-title":"Overcoming multidrug resistance using small molecule dynamic inhibitors by hijacking nascent and inducing turnover of mature ABCG2 for degradation in lysosomes","volume":"84","author":"Dong","year":"2026","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.yexcr.2026.115098_bib54","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3892\/or.2015.3767","article-title":"Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer","volume":"33","author":"Imamura","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.yexcr.2026.115098_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1553477","article-title":"Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model","volume":"8","author":"Ayuso","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.yexcr.2026.115098_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101162","article-title":"TGF-\u03b2\/activin signaling promotes CDK7 inhibitor resistance in triple-negative breast cancer cells through upregulation of multidrug transporters","volume":"297","author":"Webb","year":"2021","journal-title":"J. Biol. Chem."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482726002156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482726002156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:33:53Z","timestamp":1782606833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482726002156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0014482726002156"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2026.115098","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vactosertib reverses ABCG2-mediated multidrug resistance through dual inhibition of drug efflux and transporter expression","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2026.115098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115098"}}